A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT01554982

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01554982
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01554982. Allocation not applicable; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2016-07-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Condition
End Stage Renal Disease
Condition
Kidney Failure
Condition
Renal Failure
Condition
Hyperphosphatemia
Condition
ESRD
Intervention (Drug)
ferric citrate
Lead sponsor
Keryx Biopharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01554982
Content hash
5e2dfe2e8b228120d93824df30b84a1add54fe9a4e8af4ce04c29fd86d931b1e